News Torii Pharmaceutical Co., Ltd.

Equities

4551

JP3635800000

Delayed Japan Exchange Other stock markets 10:23:41 2024-04-18 pm EDT			5-day change	1st Jan Change
3,655 ^JPY	-3.18%		-7.72%	+2.53%

Feb. 13	LIM Advisors Partially Withdraws Shareholder Proposal	CI
Feb. 09	Torii Pharmaceuticals Opposes Shareholder Proposal	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LIM Advisors Partially Withdraws Shareholder Proposal	Feb. 12	CI
Torii Pharmaceuticals Opposes Shareholder Proposal	Feb. 08	CI
Final dividend	Dec. 27	FA
Torii Pharmaceutical - Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	Dec. 18	AQ
Verrica Pharmaceuticals Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208	Dec. 18	AQ
Verrica Pharmaceuticals' Partner Reports Positive Data From Phase 3 Trial of Skin Infection Treatment	Dec. 15	MT
Torii Pharmaceutical : Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	Dec. 15	PU
Torii Pharmaceutical Co., Ltd. Announces Positive Top-Line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan	Dec. 15	CI
Torii Pharmaceutical : Signing of an Agreement for the Exclusive Development and Commercialization of GRAZAX®,an Allergen Immunotherapy (Sublingual Immunotherapy) Drug for Grass Pollinosis in Japan	Dec. 12	PU
ALK Abello Adds Grass Pollen Allergy Drug to Torii License Deal in Japan	Dec. 12	MT
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	Dec. 12	CI
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise	Nov. 30	MT
Torii Pharmaceutical : Financial Results for the First Nine Months of Fiscal Year Ending December 2023	23-10-31	PU
Torii Pharmaceutical - JT Files New Drug Application of JTE-061 Cream, Aryl hydrocarbon Receptor agonist, for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	23-09-18	AQ
Torii Pharmaceutical : JT Files New Drug Application of JTE-061 Cream,Aryl hydrocarbon Receptor (AhR) agonist,for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	23-09-15	PU
Ex-dividend day for interim dividend	23-06-28	FA
Torii Pharmaceutical : Financial Results for the First Three Months of Fiscal Year Ending December 2023	23-04-28	PU
Torii Pharmaceutical Announces Voting Results	23-03-30	CI
Torii Pharmaceutical : Views on Report from ISS, a Proxy Advisory Firm, On Proposals for ’s General Meeting of Shareholders	23-03-16	PU
Torii Pharmaceutical : Notice of the Opinion of the Board of Directors Regarding the Shareholder Proposal	23-02-17	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Torii Pharmaceutical Co., Ltd.

Equities

4551

JP3635800000

Summary

Filters